Exome sequencing of samples taken at multipl time points to monitor therapy response in AML

Study ID Alternative Stable ID Type
EGAS00001001948 Other

Study Description

As part of our individualized systems medicine program, personalized treatment options are identified and administered to chemorefractory AML patients based on exome sequencing and ex-vivo drug sensitivity and resistance testing data. In this study, we developed this approach further to take into account clonal heterogeneity and analyzed responses of 13 AML patients to chemotherapy and six patients to targeted treatments by using exome and ultra-deep amplicon resequencing. The data submitted includes fastq files from exome sequencing of multiple time-point samples collected from the 13 patients. In this study we identified rare subclonal variants present at diagnosis or later relapse samples and developed a correlation-based method to compare subclonal responses in serial samples across multiple time-points. Significant subclone-specific responses were observed subsequent to chemotherapy and specifically to targeted therapy in five patients.

Study Datasets 1 dataset.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
In this dataset, exome sequencing of bone marrow samples taken during multiple timepoints of disease progression from 13 AML patients are present. These samples were take either before/after treatment, at diagnosis or at relapse.
Illumina Genome Analyzer IIx,Illumina HiSeq 1500,Illumina HiSeq 2500 32

Who archives the data?

There are no publications available